- Home
- PRAX
as of 01-02-2026 3:30pm EST
$286.98
$7.76
-2.63%
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.0B | IPO Year: | 2020 |
| Target Price: | $373.79 | AVG Volume (30 days): | 790.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.70 - $317.72 | Next Earning Date: | 11-05-2025 |
| Revenue: | $7,463,000 | Revenue Growth: | 364.98% |
| Revenue Growth (this year): | -99.45% | Revenue Growth (next year): | 12467.71% |
AI-Powered PRAX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 77.48%
77.48%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Praxis Precision Medicines Inc. (PRAX)
Adage Capital Management, L.P.
Sell
10% Owner
PRAX Oct 16, 2025
Avg Cost/Share
$111.24
Shares
313,910
Total Value
$33,198,123.57
Owned After
2,361,485
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Adage Capital Management, L.P. | PRAX | 10% Owner | Oct 16, 2025 | Sell | $111.24 | 313,910 | $33,198,123.57 | 2,361,485 |
Latest Praxis Precision Medicines Inc. News
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
📈
AI Sentiment
Highly Positive
9/10
24/7 Wall St.
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
📈
AI Sentiment
Highly Positive
8/10
Compare PRAX vs Leading Stocks
See how PRAX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.